SCHEMBL13772115

SCHEMBL13772115

CCCNCC1CCNCC1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GNAO1 P09471 7/20 0.70
GNAI3 P08754 6/20 0.70
GNAI1 P63096 6/20 0.70
SAT1 P21673 1/20 0.45
PRMT5 O14744 1/20 0.44
WDR77 Q9BQA1 1/20 0.44
ALOX15 P16050 2/20 0.43
ANPEP P15144 1/20 0.43
ERAP2 Q6P179 1/20 0.43
TSHR P16473 1/20 0.41
EPHX1 P07099 3/20 0.38
EPHX2 P34913 1/20 0.37
SLC6A1 P30531 2/20 0.36
GABRA5 P31644 2/20 0.36
GABRB2 P47870 2/20 0.36
SLC6A12 P48065 2/20 0.36
SLC6A11 P48066 2/20 0.36
SLC6A13 Q9NSD5 2/20 0.36
GABRA1 P14867 1/20 0.36
GABRR1 P24046 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25582070 0.88 GNAI3 (0.56) GNAO1GNAI3GNAI1SAT1PRMT5
SCHEMBL7328368 0.88 GNAO1 (0.83) GNAO1GNAI3GNAI1SAT1PRMT5
SCHEMBL6968840 0.88 GNAI3 (0.56) GNAO1GNAI3GNAI1SAT1PRMT5
SCHEMBL3687401 0.86 GNAO1 (0.93) GNAO1GNAI3GNAI1SAT1PRMT5
SCHEMBL3652066 0.84 GNAO1 (0.96) GNAO1GNAI3GNAI1SAT1TSHR
SCHEMBL2839904 0.84 GNAO1 (0.96) GNAO1GNAI3GNAI1SAT1TSHR
SCHEMBL11420212 0.84 SAT1 (0.60) GNAO1GNAI3GNAI1SAT1EPHX1
SCHEMBL95570 0.84
SCHEMBL4711032 0.82 GNAI3 (0.58) GNAO1GNAI3GNAI1SAT1PRMT5
SCHEMBL5963013 0.82 GNAI3 (0.75) GNAO1GNAI3GNAI1SAT1PRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2023-03-30 US disclosed
EP-3105226-B1 CYCLOPROPYLAMINES AS LSD1 INHIBITORS INCYTE CORP (US) 2019-09-04 EP disclosed
EP-2699546-B1 GAS CAPTURE PROCESS COMMONWEALTH SCIENT & INDUSTRIAL RESEARCH ORGANISATION (AU) 2019-06-26 EP disclosed
WO-2018046409-A1 8-(AZETIDIN-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-03-15 WO disclosed
US-9409122-B2 Gas capture process COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2016-08-09 US disclosed
US-20140127103-A1 GAS CAPTURE PROCESS COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) 2014-05-08 US disclosed
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170832-A1 HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY HSD17B1, HSD11B1, HSD3B1 GNAO1 448/4885GNAI3 1745/4885GNAI1 1270/4885
US-20230097358-A1 INDAZOLE BASED COMPOUNDS AND ASSOCIATED METHODS OF USE LRRK2, CRBN, MDM2 GNAO1 2111/4885GNAI3 935/4885GNAI1 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.